Lumida
/GLUE
⌘K
Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics Inc

GLUE
$14.07USD-1.75%-0.25 today

MARKET CAP

1.2B

P/E (TTM)

FWD P/E

DAY RANGE

$14 – $15

52W RANGE

$5
$26

AI Summary

Stalk
Sell NowMedium

GLUE is in a Stage 3 distribution after support failure and is trading below declining 9/20 EMAs, confirming medium-term bearish control. Short-term price rejects into the 9/20 EMA zone, creating favorable timing to sell now on rallies into resistance. Watch for a sustained close above the EMAs to invalidate this bearish view.

  • Phase 2 MODeFIRe-1 trial for MRT-2359 initiated; data due H2 2024.
  • Novartis collaboration accelerates MRT6160 research and market positioning.
  • Price-to-Sales ratio of 43.2× far exceeds industry average (~13.3×).
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2024FY 2025TREND
Sales, Adj.$75.6M$123.7M
YoY %+63.5%
P / Sales6.8x10.5x
EV / Sales6.7x11.2x
Gross Profit, Adj.$75.6M$123.7M
YoY %+63.5%
Margin %100.0%100.0%
EV / Gross Profit6.7x11.2x
EBITDA, Adj.$-73.0M$-45.9M
YoY %+46.8%+37.2%
Margin %-96.5%-37.1%
EV / EBITDA-6.9x-30.3x
EBIT$-81.1M$-54.2M
YoY %+43.4%+33.2%
Margin %-107.3%-43.8%
EV / EBIT-6.2x-25.6x
Net Income$-72.7M$-38.6M
YoY %+46.3%+46.9%
Net Margin-96.1%-31.2%
EPS (GAAP)-$0.98-$0.46
YoY %+62.7%+53.1%